Tiziana Life Sciences Stock News

  Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference in Sweden   Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer's disease (AD) Modulation of neuroinflammation may be synergistic to existing treatments...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that positive data from a study of intranasal anti-CD3 monoclonal antibody (mAb) in an animal model of Alzheimer's disease will be presented at an

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has received feedback based on the US Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of intranasal fora

Tiziana Life Sciences Ltd (NASDAQ:TLSA). said it has received positive coverage in an article on Forbes which highlighted foralumab, its unique intranasal monoclonal antibody currently in clinical de

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a publication in the preeminent journal Proceedings of the National Academy of Sciences (PNAS) that illustrates the immunological basis of the me

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the Investigational New Drug (IND) application filing for its milciclib treatment in combination with gemcitabine for non-small cell lung cancer

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has hailed news of an improvement in a multiple sclerosis patient being treated with intranasal foralumab in a clinical study. This second expanded access pati

Tiziana Life Sciences Ltd (NASDAQ:TLSA) highlighted milestones from the first six months of 2022 as the company advances its pipeline of next-generation therapeutics and diagnostics for oncology and

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced completion of the in-life portion of a 13-week, Good Laboratory Practice (GLP) foralumab intranasal pre-clinical study in transgenic HuGEMM CD3 m

NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel rout

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has published a scientific article in the peer-reviewed journal Frontiers in Immunology, showing a favorable safety profile for intranasally administere

High conviction is what it takes to build and launch the best ETFs at GraniteShares. And that's a solution for disappointing 60/40 portfolios.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the start of enrollment of the first patient cohort in its intermediate-size patient population expanded access program to evaluate foralumab in n

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that it plans to submit an Investigational New Drug Application (IND) for a phase 1 trial of intranasal foralumab in Alzheimer's disease patients.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has presented posters on intranasal foralumab at the Preserving the Brain scientific conference, a scientific forum and exhibit on neurodegenerative diseases as